Balanced news tone
News Sentiment
INDP sentiment intelligence
Indaptus Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
46
Balanced news tone
45 relevant articles
News tone and price action are not far from neutral.
76/100 classification confidence.
directly relevant articles
high-authority source matches
-3.8% over one week, -35.1% over four weeks, trend active, and below fair value.
Indaptus Therapeutics (NASDAQ: INDP) seeks approval for 2026 equity plan
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
76/100 classification
One-week reaction
-3.8%
Price reacting lower
Trend fit
Trend active
-35.1% over four weeks
Fair value
-91.7%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
7
Neutral
25
Negative
13
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Stock Titan
Direct company coverage
Indaptus Therapeutics (NASDAQ: INDP) seeks approval for 2026 equity plan
Indaptus Therapeutics (NASDAQ: INDP) is seeking shareholder approval for its 2026 Equity Incentive Plan at the upcoming annual meeting on August 10, 2026. The plan will initially reserve 13,324,232 shares and includes an annual automatic increase of 5% of outstanding shares from
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 16 Jul 2026 20:10
- Source
- Stock Titan
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Simply Wall Street
Direct company coverage
Indaptus Therapeutics (Nasdaq:INDP) - Stock Analysis
This article provides a detailed stock analysis of Indaptus Therapeutics (INDP), a clinical biotechnology company developing anti-cancer and anti-viral immunotherapy products. It highlights significant risks such as shareholder dilution, declining earnings, and a short cash runwa
- Tone
- Negative 15/100
- Event
- Earnings
- Published
- 09 Jul 2026 17:09
- Source
- Simply Wall Street
Simply Wall Street
Direct company coverage
Insider Traders Lose US$34k As Indaptus Therapeutics Drops
Indaptus Therapeutics saw its stock price drop by 11%, leaving insiders, who had bought US$50.4k worth of shares at an average of US$8.30, with a current investment value of only US$16.2k. Despite this loss, the article notes that the single insider buyer, Jeffrey Meckler, purcha
- Tone
- Negative 37/100
- Event
- Market update
- Published
- 08 Jul 2026 11:39
- Source
- Simply Wall Street
Moomoo
Direct company coverage
Indaptus Therapeutics (INDP) News Flow
This article provides an analysis of recent news and stock performance for Indaptus Therapeutics (INDP). It highlights a significant trading volume increase and outlines upcoming clinical catalysts that could impact the stock. The author purchased shares and reiterates a long-ter
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 29 Jun 2026 14:12
- Source
- Moomoo
Investing.com South Africa
Direct company coverage
Form 13D/A Indaptus Therapeutics For: 26 June By Investing.com
This article from Investing.com announces the filing of a Form 13D/A for Indaptus Therapeutics, dated June 26. The piece is notably brief, providing only the title, publication date, and a Reuters copyright image reference, along with a link to the company's stock symbol (INDP).
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 12:41
- Source
- Investing.com South Africa
Investing.com South Africa
Direct company coverage
Form S-3 Indaptus Therapeutics Inc For: 26 June By Investing.com
This article reports on the filing of Form S-3 by Indaptus Therapeutics Inc. on June 26. The brief announcement provides the company and date of the filing. It also includes market data and popular news headlines from Investing.com.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 12:11
- Source
- Investing.com South Africa
Stock Titan
Direct company coverage
Yun Yao (NASDAQ: INDP) reports 31.5% Indaptus stake change
Yun Yao filed an Amendment No. 2 to her Schedule 13D for Indaptus Therapeutics, Inc. (INDP), reporting a 31.51% beneficial ownership stake, which is 41,991,000 shares. This decrease from her previous percentage is due to Indaptus's private placement of additional shares on June 1
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 27 Jun 2026 12:11
- Source
- Stock Titan
Stock Titan
Direct company coverage
Sino Lion Ventures (INDP) files amended 13D on 38,895,000 shares
Sino Lion Ventures Limited and Chenhao Xu have filed an amended Schedule 13D for Indaptus Therapeutics, Inc., reporting beneficial ownership of 38,895,000 shares, representing 29.19% of the company. Their percentage ownership decreased due to Indaptus's private placement on June
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 02:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Indaptus (INDP) investor Ting Yang stake falls to 8.44% after share issuance
Indaptus Therapeutics investor Ting Yang's ownership stake has decreased to 8.44% of the outstanding shares, totaling 11,250,000 shares, as of June 24, 2026. This reduction, a drop of more than 1%, is attributed to a private placement completed by Indaptus on June 17, 2026, which
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 27 Jun 2026 00:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Indaptus Therapeutics (INDP) CEO details 8.44% common stock stake
Indaptus Therapeutics CEO Junyi Dai reported a beneficial ownership of 8.44% of the company's common stock, totaling 11,250,000 shares, as of June 24, 2026. This stake was acquired through the conversion of Series AA and Series AAA Preferred Stock, purchased for $1,156,642.43 usi
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 27 Jun 2026 00:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Indaptus Therapeutics (INDP) registers 18.864M shares; clinical program paused
Indaptus Therapeutics (INDP) has registered 18.864 million shares for resale by selling stockholders, converted from Series AA and AAA preferred stock. The company will not receive any proceeds from these resales. Additionally, Indaptus has paused the clinical development of its
- Tone
- Negative 35/100
- Event
- Market update
- Published
- 26 Jun 2026 21:10
- Source
- Stock Titan
TradingView
Direct company coverage
Indaptus Therapeutics - To Issue 20 Million Shares At $0.6 Per Share - SEC Filing
Indaptus Therapeutics announced its intention to issue 20 million shares at a price of $0.6 per share, as revealed in a recent SEC filing. The information was initially reported by Reuters and is now available through TradingView News. This financial move marks a notable developm
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 25 Jun 2026 22:41
- Source
- TradingView
TradingView
Direct company coverage
Revenue per share of Indaptus Therapeutics, Inc. – NASDAQ:INDP
This article provides financial information for Indaptus Therapeutics, Inc. (NASDAQ: INDP), specifically focusing on its revenue per share. The content appears to be a stub or a data point from a financial platform, indicating a period value, change, and change percentage.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 21:09
- Source
- TradingView
Moomoo
Direct company coverage
INDAPTUS THERAPEUTICS - TO ISSUE 20 MLN SHARES AT $0.6 PER SHARE - SEC FILING
Indaptus Therapeutics plans to issue 20 million shares at a price of $0.6 per share. This information was disclosed in a recent SEC filing. The offering aims to raise capital for the company.
- Tone
- Negative 38/100
- Event
- Market update
- Published
- 25 Jun 2026 11:10
- Source
- Moomoo
TradingView
Direct company coverage
Indaptus Therapeutics Raises $12 Million in Offshore Private Placement at $0.60 Per Share
Indaptus Therapeutics has successfully raised approximately $12 million through an offshore private placement, selling 20,000,000 common shares at $0.60 per share to non-U.S. accredited investors. This offering represented less than 20% of outstanding shares and involved no commi
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 24 Jun 2026 19:40
- Source
- TradingView
Stock Titan
Direct company coverage
Indaptus Therapeutics (INDP) sells 20M shares in $12M Regulation S private placement
Indaptus Therapeutics (INDP) announced a Regulation S private placement, selling 20 million common shares at $0.60 each to non-U.S. accredited investors, raising approximately $12 million in gross proceeds. This transaction represents less than 20% dilution of outstanding shares
- Tone
- Positive 60/100
- Event
- Market update
- Published
- 24 Jun 2026 19:40
- Source
- Stock Titan
Stock Titan
Direct company coverage
Indaptus Therapeutics (INDP) asks shareholders to approve $300M PIPE, equity plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Stock Titan
TradingKey
Direct company coverage
Indaptus Therapeutics Inc (INDP) Institutional Confidence
The article provides an overview of Indaptus Therapeutics Inc (INDP)'s institutional confidence, highlighting its TradingKey Stock Score and shareholder activity. It lists significant individual and institutional shareholders, including changes in their holdings. The company's st
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 10:09
- Source
- TradingKey
TradingKey
Direct company coverage
Indaptus Therapeutics Inc (INDP) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Indaptus Therapeutics Inc (INDP), noting that no earnings forecast score is currently available, contrasting with the biotechnology industry average. Analysts predict a price target of $10.00 for INDP. The report also highlights past
- Tone
- Negative 39/100
- Event
- Earnings
- Published
- 18 Jun 2026 10:09
- Source
- TradingKey
TradingKey
Direct company coverage
Indaptus Therapeutics Inc (INDP) Valuation: PE, PB & Fair Value Analysis
Indaptus Therapeutics Inc (INDP) has a current valuation score of 6.58, placing it 321st out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio is -0.35, which is notably lower than its recent high and higher than its recent low. Key valuation metric
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 18 Jun 2026 10:09
- Source
- TradingKey
GlobeNewswire
Direct company coverage
Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders
Abbott Cooper PLLC has announced an investigation into Indaptus Therapeutics, Inc. (Nasdaq: INDP) on behalf of stockholders who held shares prior to December 22, 2025. The investigation will determine if Indaptus's Board violated its fiduciary duties regarding a private placement
- Tone
- Negative 28/100
- Event
- Regulatory and legal
- Published
- 18 Jun 2026 02:40
- Source
- GlobeNewswire
Minichart
Direct company coverage
Indaptus Therapeutics, Inc. Files Form 8-K Announcing CEO Change – Junyi Dai Appointed CEO
Indaptus Therapeutics, Inc. filed an 8-K report detailing leadership changes, specifically referencing Item 5.02, which pertains to the departure or appointment of officers. The filing confirms the company is not an emerging growth company and does not indicate any major corporat
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jun 2026 10:13
- Source
- Minichart
Stock Titan
Direct company coverage
Leadership shifts at Indaptus Therapeutics (NASDAQ: INDP) as directors and COO exit
Indaptus Therapeutics (INDP) reported several leadership changes, including the resignations of directors David E. Lazar and Avraham Ben-Tzvi, effective June 5, 2026, and COO Walt A. Linscott, effective June 1, 2026. Linscott will transition to a strategic advisory consulting rol
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jun 2026 20:39
- Source
- Stock Titan
Moomoo
Direct company coverage
Indaptus Therapeutics (INDP) Jumps 53.8% Amid Heavy Volume as Investors Focus on Financing/strategic-option Uncertainty
Indaptus Therapeutics (INDP) stock jumped 53.8% on heavy volume following its reverse stock split. The company is exploring financing and strategic options, raising investor interest in potential future developments. This significant price movement highlights the market's respons
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 Jun 2026 03:09
- Source
- Moomoo
Finviz
Direct company coverage
INDP - Indaptus Therapeutics Inc Stock Price and Quote
This page provides a comprehensive overview of Indaptus Therapeutics Inc (INDP) stock, including its latest price, financial metrics, insider ownership, and recent news. The article highlights the company's focus on developing novel anti-cancer and anti-viral immunotherapies, wit
- Tone
- Positive 64/100
- Event
- Market update
- Published
- 02 Jun 2026 16:10
- Source
- Finviz
AlphaStreet
Direct company coverage
Indaptus Therapeutics Releases Q1 2026 Financial Results
Indaptus Therapeutics, Inc. reported its Q1 2026 financial results, showing a significantly narrower loss of $0.23 per share, an improvement from $9.11 in the prior year. The clinical biotechnology company, trading as INDP, posted a net loss of $2.5M as it continues to advance it
- Tone
- Positive 71/100
- Event
- Earnings
- Published
- 16 May 2026 07:10
- Source
- AlphaStreet
Stock Titan
Direct company coverage
Indaptus Therapeutics (NASDAQ: INDP) cuts R&D, warns on cash runway
Indaptus Therapeutics (INDP) reported a Q1 2026 net loss of $2.54 million, an improvement from the previous year, largely due to a significant reduction in R&D spending as clinical activity was wound down. The company's cash and cash equivalents dwindled to $1.50 million, and it
- Tone
- Negative 14/100
- Event
- Balance sheet
- Published
- 16 May 2026 06:39
- Source
- Stock Titan
Minichart
Direct company coverage
Indaptus Therapeutics, Inc. Reports Substantial Doubt About Going Concern and Highlights Key Risks in Q1 2026 10-Q Filing
Indaptus Therapeutics, Inc. has reported a net loss of $2.54 million for Q1 2026 and an accumulated deficit of $83.83 million, leading to a substantial doubt about its ability to continue as a going concern. The company's stockholders' equity decreased significantly, and it antic
- Tone
- Negative 9/100
- Event
- Balance sheet
- Published
- 16 May 2026 05:39
- Source
- Minichart